Lycia Therapeutics, Inc. LYCA
31.30 USD +0.94 (+3.10%)
At closeNov 10, 2026, 4:03 PM EST
30.83 -0.47 -1.50%
After hours · Nov 10, 4:03 PM ET
29.88 Day range 31.57
22.19 52-week range 36.49
- YTD
- +4.33%
- 1 year
- +4.33%
News
globenewswire.com Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
barrons.com Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
seekingalpha.com U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. One IPO is currently scheduled for the week ahead as investors continue to hold…
globenewswire.com Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
reuters.com Drug developer Lycia Therapeutics targets $938 million valuation in US IPO Drug developer Lycia Therapeutics targets $938 million valuation in US IPO